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Abstract:  
 
This paper investigates the diversity management in pharmaceutical small and medium-sized 
enterprises and specifically of their official entities in Central and Eastern Europe.   
 
It argues that diversity management measures vary between headquarters and subsidiaries 
as the country regulations on diversity are different across Europe. Paper employs 
descriptive statistics showing that the local subsidiaries in Central Europe refer mainly to 
the code of conduct of the parent company without having their own code of conduct. 
 
The paper results demonstrate that diversity management measures differ between 
headquarters and subsidiaries and many of the diversity dimensions are not covered in the 
subsidiaries across this region. 
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1. Introduction  
 
Today organizations are facing many endeavours in regard to diversity management. 
There are quite many major changes in workforce structure along with globalized 
markets and international competition. Thus, the increasing amount of diversity 
organizations must manage, both internally and externally. Many diversity 
specialists, scholars and business leaders argue that industries and organizations 
interested in being competitive and sustainable in the twenty-first century need to 
take competitive advantage of a diverse workplace (Soutar, 2004; Yang, 2005). But 
to do so successfully, leaders and human resources managers have to reshape their 
approaches in regard to management and leadership (Jones, 1989).  
 
This new way of thinking about diversity focuses on meeting the needs of the 
individual and not so much on an HR-centered initiative. Today, it is not only about 
having diversity within a company but leveraging that diversity to produce better 
products and services. 
 
It is crucial to hire and maintain a diverse workforce, so gender and racial/ethnic 
initiatives will be launched and maintained into the foreseeable future. There is 
much to learn from leaders in diversity and inclusion, but it is important to 
remember that every company’s Diversity & Inclusion initiatives will look different. 
Therefore, strategic diversity management initiatives supposed to address the 
specific industry and the companies’ needs in terms of diversity.  This however, also 
means that global strategies have to be adopted local small and medium-sized 
companies (SMEs).  
 
The paper aim is to investigate what dimensions of diversity management are 
reflected in the US-based pharmaceutical companies in their US headquarters and 
CEE respective subsidiaries.  Further, the study raises the question if US pharma 
companies are managing diversity locally or globally in terms of practices, 
approaches and techniques. 
 
2. Literature review 
 
A diversity management strategy is of paramount importance for an organization to 
effectively manage a diverse workforce by promoting personal and professional 
development and create a positive work environment. Organizations need to be 
mindful of removing any barriers that may hinder progress such as categorizing 
people into certain positions, always recruiting from the same source, and grooming 
and developing certain people ‘liked’ by senior management. 
 
It needs to be remembered that diversity is not an ‘initiative’ or a ‘project,’ it needs 
to be an ongoing core aim and core process. An effective diversity management 
strategy has a positive effect on cost reduction, creativity, problem solving and 
organizational flexibility (Mannix and Neale, 2005). 
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As all industries, the pharmaceutical industry is faced with the challenges presented 
by today’s economic climate. This, in conjunction with workforces from different 
ethnic groups, backgrounds, religions and others catering for a diverse customer 
base, calls for strategic diversity management at all levels of the company and in all 
subsidiaries.  
 
Why should pharma business be concerned with diversity? The pharmaceutical 
industry needs all employees to perform well to sustain success, and for them to 
perform well they need to feel valued. All employees need to be treated differently 
in ways that are fair and bring out the best in them, but at the same time meet the 
business needs and objectives. The mindset here has to be one of thinking of 
differences and communalities as assets and maintaining a balance with personal and 
business responsibilities creating win win solutions. To date many pharmaceutical 
SMEs have used diversity management as a key to improve the health and well-
being of the world through the passion of its employees. For example, diversity is a 
central theme of the culture across the Johnson & Johnson family of companies, as 
well as Pfizer. 
 
Many global corporations have realized that in order to manage diversity in the 
headquarters and in their subsidiaries, they have always to adapt to the local 
conditions and norms. Hence, it requires extremely individual approach as many 
CEE countries still do not possess legal acts and policies on many diversity 
dimensions as LGBT, minorities and others, which pinpoint the rule that ‘One size 
does not fit all’ in terms of diversity management approach. To act locally means 
conforming of national strategies and policies that take into account the particular 
location’s core diversity measures e.g. gender quotas, work opportunities during 
maternity, women leadership initiatives and others. This means that all diversity 
measures will comply and intertwine with the legal and cultural policies and norms 
(Mortimore, 2014). Diversity management dynamics vary considerably worldwide 
in terms of pre-requisites for diversity management policies and initiatives 
implementation. The main idea around diversity and inclusion programs is to 
maximize the productivity and performance of all employees to fulfil the company 
assignments and enhance business results. The organizations cannot expect any 
major success without recognizing, tolerating and balancing diversity management 
practices (Kirton and Greene, 2015; Ivanova et al., 2017; Shekhovtsov et al., 2017). 
 
Around the world the issues of gender and, increasingly, age and disability are the 
strongest elements of diversity. The issue of the ageing workforce is also one for 
nearly every industrialized country. Maintaining an adequate labour force will 
increase competition for talent, and require organizations to retain older workers and 
tap into underutilized sources of talent – namely women, ethnic minorities, 
immigrants and people with disabilities. So the workplace will become increasingly 
diverse. If not managed well, this diversity will detract rather than enhance business 
results. 
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US pharma provider Johnson & Johnson with many subsidiaries in the CEE region, 
for example, realized that to be successful in global diversity, it needed culturally 
appropriate efforts launched for every region. The company was struggling to 
combine its diversity efforts in the United States and Europe, so it conducted its 
first-ever live video conference on mutual perceptions, diversity and respect. Clients 
and employees reported increased productivity, and over 100 survey participants 
reported the conference was the most valuable training they had ever experienced. 
 
3. Methods 
 
For the purpose of the paper, is collected secondary data from the top ten 
pharmaceutical US companies with operations in Central and Eastern European 
SMEs. The US pharma companies are among the top in the CEE region in terms of 
number of employees, number of subsidiaries, turnover and volume of sales. The 
data has been gathered from the companies’ websites, social networks and SMEs’ 
code of conducts and from other secondary based sources as Bloomberg, Fortune 
2000, Thomson Reuters One and social network LinkedIn (Wroblowska 2016c). In 
the paper we collected the following information: existence of local and global 
diversity management strategy and corresponding measures with regard to gender, 
age, sexual orientation, (dis)ability, religion and ethnicity. We have limited the 
exploration to those diversity dimensions which are covered by the EU diversity 
legislation. In the paper the companies’ websites, code of conducts and other 
secondary based sources have been analyzed in terms of diversity management 
measures. 
 
4. Results and Discussion  
 
‘Glocal’ as a term is explained as a connection between global and local practices 
(Swyngedouw, 1997b). Historically US based corporations have introduced 
diversity management measures and in many regions of the World, it is very 
difficult to state that respective countries possess specific diversity management 
measures. It raises the question if we can speak about local diversity management.  
 
Many countries as China, India, Russia and others do not have local diversity 
management tools, which makes clear why we cannot talk about local diversity 
management. Moreover, CEE region has its own specifics on Diversity 
management, which makes the region unique in terms of existence and possible 
implementation of diversity measures and practices. Having analyzed the code of 
conducts of the selected US pharmaceutical companies, it is obvious that the 
companies possess code of conducts on their domicile website.  
 
Also, on the selected companies’ websites we can find significant amount of 
information on diversity and specifically how the companies are managing diversity 
globally. At the same time, in majority of the companies’ website there are 
information on specific diversity management measures as trainings, awards, 
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programs and other initiatives referring to many of the diversity dimension. Thus, on 
a global level the US pharma companies are putting significant efforts into 
promoting diversity and applying respective measures towards increasing integrity, 
transparency and staying compliant with their strategies and code of conducts. In the 
US-based pharma companies more dimensions of diversity are reflected and 
included in the code of conducts in compare to their branches across the CEE 
region.Moreover, the selected companies demonstrate that for them is very 
important to manage diversity globally in the context of human resource 
management and specifically to equal employment opportunities, inclusion and 
minorities, etc. 
 
Based on the same companies’ analysis in terms of code of conducts, local websites 
of their subsidiaries in the CEE, we can state different approach on managing 
diversity within the region. Any of the selected US pharma companies does not have 
fully translated code of conducts into any of the CEE languages, whereas the CEE 
subsidiaries and SMEs refer to their US parent code of conduct. In majority of the 
CEE countries Diversity management is still under searched and there is no 
information on how companies should refer to diversity dimension as sexual 
orientation, transgender rights, etc.  
 
It stems from the fact that in the CEE region in many of the countries there are no 
official regulations, directives or normative documents, which are dealing with 
diversity dimensions such as sexual orientation, minorities rights, disability and 
others due to the fact that either the countries have been post-Soviet, and all this has 
prohibited or due to the fact that the countries are relatively homogeneous in terms 
of religion, ethnicity, culture and life style.  
  
Almost all studies on diversity management have been done in Western Context and 
only a few exist for other cultures. As most Western countries have 
multiculturalism, we cannot state the same for CEE region, where the population are 
much more homogenous, and level of diversity is much lower in terms of 
nationalities, religion, ethnicity and other diversity dimensions representations. It is 
not new to the practitioners and academicians that diversity management is a 
Western Concept but based on the literature review combined with postcolonial 
perspectives this thought emerges. Referring to the US Pharma subsidiaries and 
SMEs in the CEE, it is evident that there is lack of information on diversity on their 
websites and just few of them publish information what initiatives and programs 
have been devoted to managing diversity within the headquarter.   
 
Interestingly, most of the Code of Conducts in the US pharma subsidiaries across the 
CEE region do not contain any information in several diversity dimensions as shown 
in Table 4 but at the same time there is approved official EU Antidiscrimination 
Directive (RL 2000/78/EG). This contradiction sheds a light on disparities in the 
diversity management practices between the Headquarters of the US pharma 
companies and their subsidiaries and their SMEs in the CEE region. 
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5. Conclusion  
 
The study argues that the US Pharmaceutical small and medium-sized companies in 
the CEE manage differently diversity on a global and local level but at the same time 
many of the diversity dimensions have been translated into the local conditions of 
the region and there are trends nowadays that these companies will be referring more 
and more to wider range of diversity dimensions because they know that if they 
would like to be competitive and successful in the region they have to fuse the local 
with the global techniques and measures on managing diversity. All in all, this 
increase of diversity measures with regard to those dimensions, which got less 
attention in the subsidiaries so far, may be argued with increasing societal and 
political pressure. From a neo-institutional perspective (Walgenbach and Meyer 
2008), such expectations for organizations work as driver in order to set up or 
sustain societal legitimacy of diversity. The paper concludes with the facts that many 
US Pharmaceutical SMEs in Central and Eastern Europe apply completely different 
measures and tools on managing diversity locally, which stems from the local labour 
market requirements and historical economic development of the region itself. 
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APPENDIXES:  
 
Table 1. List of US-based Pharmaceutical companies having subsidiaries or SME. in CEE 
region 
Company Name Subsidiaries’ Locations HQ’s Location 
Pfizer Austria, Bulgaria, Romania US 
Johnson&Johnson Austria,Czech Republic, 
Slovakia, Poland 
US 
Baxter Austria, Bulgaria, Czech 
Republic, Poland 
US 
Bristol-Myers Squibb Czech Republic, Slovakia US 
Lilly Czech Republic, Romania US 
Amgen Hungary, Austria, Bulgaria US 
AbbVie Czech Republic,Hungary US 
Merck & Co. Austria. Bulgaria, Czech 
Republic 
US 
Biogen Idec Austria, Croatia, Bosna & 
Herzegovina 
US 
Actavis Austria, Bulgaria, Hungary. US 
Source: Author, N=10. 
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Table 2. List of US pharmaceutical companies and their code of conducts in the US & CEE 
Company Name Code of Conduct in the US Code of Conduct in the 
CEE region 
Pfizer X - 
Johnson&Johnson X - 
Baxter X - 
Bristol-Myers Squibb X - 
Lilly X - 
Amgen X - 
AbbVie X - 
Merck & Co. X - 
Biogen Idec X - 
Actavis X - 
Source: Author, N=10. 
 
Table 3. Existing diversity dimension in the US pharma headquarters’ companies 
Company Name Gender Age Disability Minorities Sexual 
orientation 
Religion 
Pfizer X X X X - - 
Johnson&Johnson X X X X X - 
Baxter X X X X - X 
Bristol-Myers Sq.               X X X X X X 
Lilly X X X X - - 
Amgen X X X - - - 
AbbVie X X X X - - 
Merck & Co. X X X X X X 
Biogen Idec X - - - - - 
Actavis X X X X - - 
Source: Author, N=10. 
 
Table 4: Sex, gender, sexual orientation in the selected Code of Conducts 
Company Name Sex Gender Age Minorities Religion Sexual 
orientation 
US Headquarters 10 10 9 9 6 6 
CEE subsidiaries 2 6 1 1 0 1 
Source: Author, N=10. 
 
   
 
  
  
